Since the conventional treatment options for ADAMTS13-related bleeding disorder have not been always feasible and successful in patients receiving mechanical circulatory assist device support, we attempted to develop a new therapeutic agent by constructing humanized anti-ADAMTS13 antibodies in this study. This evidence concerns the gene ADAMTS13 and hemorrhagic disease.